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Abstract 
This paper is organized jointly by the European Academy of Dermatology and Venereology 
(EADV) Task Force (TF) on Quality of Life (QoL) and Patient Oriented Outcomes and the 
EADV TF on acne, rosacea and hidradenitis suppurativa (ARHS). The purpose of this paper is to 
present current knowledge about QoL assessment in HS, including data on HS-specific health-
related (HR) QoL instruments and HRQoL changes in clinical trials, and to make practical 
recommendations concerning the assessment of QoL in people with HS. 
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HS results in significant quimp that is higher than in most other chronic skin diseases. HS impact 
in published studies was assessed predominantly (84% of studies) by the Dermatology Life 
Quality Index (DLQI). There is a lack of high quality clinical trials in HS patients where HRQoL 
instruments have been used as outcome measures. One double-blind randomized placebo-
controlled trial on infliximab with low number of participants reported significantly better 
HRQoL improvement in the treatment group than in the placebo group. Well-designed clinical 
studies in HS patients to compare different treatment methods, including surgical methods and 
assessing long-term effects are needed.  Because of lack of sufficient validation, the Task Forces 
are not at present able to recommend existing HS-specific HRQoL instruments for use in clinical 
studies.  The EADV TFs recommend the dermatology-specific DLQI questionnaire for use in HS 
patients. The EADV TFs encourage the further development, validation and use of other HS-
specific, dermatology-specific and generic instruments but such use should be based on the 
principles presented in the previous publications of the EADV TF on QoL and Patient Oriented 
Outcomes. 
Introduction 
Hidradenitis suppurativa/acne inversa (HS) has been, since its first description in 1839 by 
Velpeau,1 a medical stepchild due to late diagnosis, lack of effective therapeutic regimens and no 
clear attachment to a specific medical specialty. Until recently there has been very little scientific 
interest in the disease.  However the establishment by dermatologists and patients of the 
Hidradenitis Suppurativa Foundation, Inc. in 2005 and of the European Hidradenitis Suppurativa 
Foundation e.V. in 2012, the first widely accepted definition of the disease being agreed at the 1st 
International Conference on HS Research on 2006 in Dessau, Germany2, the establishment of 
simple diagnostic criteria3, guidelines for treatment4, classification and follow-up criteria5-7 and 
the resulting interest of the pharmaceutical industry8 has catapulted HS among the diseases with 
the most growing scientific interest. From 1981 to 2005 there were about 15 publications on HS 
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identified on PubMed per year. In contrast from January 2017 to June 2018 there were 453 
publications (302 per year). 
Despite the recent focus on HS education and research, there is still a delay of seven years on 
average before the diagnosis is correctly made9, increasing the likelihood of widespread scarring. 
The long term aims of understanding HS pathogenesis and the stratification of patients according 
to their probable response to treatment, as well as the identification of biomarkers as predictive 
factors for individual treatment, requires robust relevant molecular studies. There has recently 
been the prospect of more effective treatment with the emergence of various biologics. Currently 
a core domain outcome set has been described by the Hidradenitis Suppurativa Core Outcomes 
Set International Collaboration (HISTORIC).10 
Clinical signs and the secondary effects on daily and social life of HS patients often cause 
significant impairment of health-related quality of life (HRQoL). Previous reviews on HS 
underlined the high impact of disease on patients’ lives and the absence of HS-specific HRQoL 
instruments.11-16 This present paper is organized jointly by the European Academy of 
Dermatology and Venereology (EADV) Task Force (TF) on QoL and Patient Oriented 
Outcomes and the EADV TF on acne, rosacea and HS (ARHS). The purpose of this paper is to 
present current knowledge about QoL assessment in HS, including data on HS-specific HRQoL 
instruments and HRQoL changes in clinical trials, and to make practical recommendations 
concerning the assessment of QoL in people with HS. 
 
Methods 
Members of the EADV TFs on QoL/PO and ARHS were invited to participate. A literature 
search was performed using the PubMed database, which was searched from 1980 to September 
2018 using the key word combinations: “hidradenitis suppurativa, quality of life” and “acne 
inversa, quality of life”. All publications written in English or those having English abstracts 
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were considered. All those who volunteered were allocated a section of the identified articles to 
review. 
Exclusion criteria: 
- Review articles, guidelines, protocols  
- Studies without HRQoL assessment 
- Measurement of HRQoL in conditions other than HS  
- Studies where HRQoL was measured in patients with conditions other than HS but some 
of whom may also have acne 
- Studies where HRQoL was studied in HS and other diseases but results on HS were not 
presented and/or discussed separately  
All publications were independently assessed by two co-authors. The assessments were 
compared and discrepancies discussed and resolved. The remaining publications were analyzed 
in detail and the QoL instruments used in HS were listed. For publications on HS treatment with 
no data on mean HRQoL scores, where possible the mean scores of the instruments used were 
calculated using the data of individual patients. The percentage mean change of HRQoL scores 
from baseline was calculated for each HS treatment method from data given in the included 
articles, as in a previous EADV Task Force study.17 The two-tailed paired t-test was used to 
compare mean scores before and after treatment, with results considered significant if p<0.05. 
The EADV Task Force on QoL and Patient Oriented Outcomes recommends using the word 
“quimp”18 (quality of life impairment) in routine clinical work and research19 and the word has 
been used in this article. 
Results 
From the 212 articles identified in the literature search, 142 were excluded based on the 
exclusion criteria, leaving 70 publications for the final analysis. Of these 70, the number 
published each year is presented in Figure 1. In the first, published in 2001,20 the HRQoL of 160 
HS patients was studied using the Dermatology Life Quality Index (DLQI). The highest scoring 
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DLQI item (question 1) asked about pain, soreness, stinging or itching of the skin. The mean 
total DLQI score was 8.9, meaning a moderate effect on the patient’s life, according to the DLQI 
score band descriptors.21 Mean DLQI scores in subsequent HS studies from different countries 
also reflected a moderate or very large effect on patients’ lives (Figure 2). The first study20 made 
the prescience suggestion that the DLQI may be a relevant outcome measure in future 
therapeutic trials in HS. The first such trial, published in 2006, described the efficacy of 
etanercept in symptom control in six patients with HS.22 Numerous studies on HS treatment have 
been published since.  
Clinical trials in HS 
We identified seven clinical trials of infliximab,23-29 six of adalimumab,30-35 three of 
etanercept22,36,37 and two of ustekinumab.38,39  There were five publications on surgical 
treatment,40-44  one study on combination of surgical treatment with photodynamic therapy45 and 
two other studies on photodynamic therapy.46,47  There were three studies on antibiotics,48-50 
single studies on metformin,51 PUVA,52 hyperbaric oxygen therapy,53 alitretinoin,54 acitretin,55 
ankinra,56 apremilast,57 oral zinc gluconate combined with topical triclosan58 and verapamil.59 
Detailed information on clinical trials that included ten or more HS patients are presented in 
Table 1. The percentage mean change of HRQoL scores following treatment are given in Figure 
3.  
There were four double-blind randomized placebo-controlled trials reported in HS with HRQoL 
assessment as an outcome measure. In a study of infliximab the mean DLQI improvement was 
significantly better in the treatment group than in the placebo group. The mean DLQI score 
changes were higher than the minimal clinically important difference (MCID)60  in the treatment 
group and lower than the MCID in the placebo group.23 In a study of etanercept there was no 
significant difference between the mean DLQI score of the treatment group (10 patients) 
compared to the placebo group.37 In the first study on adalimumab (15 patients) mean DLQI was 
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not significantly worse than at the baseline.32 The second publication was a post hoc analysis of 
the 2 phase 3 studies, pioneer I and II on adalimumab.34 HS patients with good clinical results 
had lower (better) DLQI scores and more of them had a DLQI score change that was greater than 
the MCID. One open-label, randomized controlled study on HS treatment with antibiotics and 
hyperbaric oxygen therapy (22 patients) or antibiotics alone (21 patients) showed significant 
improvement in DLQI scores that was greater than the DLQI MCID in both groups. However, 
the difference in QoL changes between the two groups was probably not significant. Other 
studies had an open-label design. In consequence, only one double-blind randomized placebo-
controlled study23 has shown significantly better improvement of HRQoL scores in the treatment 
group than in the placebo group. However, a limitation of that study was the low number of 
patients.  
Comparison of QoL in HS, other diseases and controls   
People with self-reported HS and other skin diseases had more impaired HRQoL than the 
general population.61 The QoL impact of HS was much greater than the impact of several other 
dermatologic conditions.62 Patients with HS have a higher HRQoL burden than patients with 
psoriasis.63 Compared with an age-standardized general population, HS patients scored 
significantly worse on several dimensions of the generic 15D questionnaire. A significant 
difference compared to psoriasis patients was detected on the sexual activity dimension.64 
Patients with HS had significantly decreased EQ-5D scores in all age groups except for 65-74 
year olds.65 The DLQI was used in parallel with the Major Depression Inventory questionnaire:66 
HRQoL was significantly more impaired in HS patients than in controls but the rate of 
depression was not significantly higher in HS patients compared to controls. Patients with HS 
presented significantly higher anxiety, depression, loneliness and social isolation scores and 
lower self-esteem scores than healthy controls.67  
Correlation of QoL and disease severity in HS patients 
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There was strong positive correlation between DLQI scores and HS clinical severity.68 Further 
analysis revealed a slight but statistically significant positive correlation between DLQI scores 
and the number of skin areas involved with HS lesions. The mean DLQI score for patients with 
anogenital involvement was 14.7 ± 7.2, whereas the mean score for other locations was 9.5 ± 7.6. 
HS was estimated as having a large or extremely large effect on the patient's life in nearly 60% 
of patients examined.68 The severity of disease, as measured by Hurley staging and the number 
of lesions, significantly correlated with the DLQI scores.69 QoL, as assessed with the DLQI, was 
also significantly different among patients in different Hurley stage groups.70 Pruritus and pain 
intensity significantly correlated with DLQI scores.71  
Studies on QoL and sexual problems in HS patients 
The DLQI was used in studies on sexual health of HS patients.72,73 HS patients had more sexual 
dysfunction and sexual distress compared to matched controls. Sexual distress was higher in 
female than in male HS patients.72 Female sex and late onset of HS were associated with poor 
sexual function. Impairment of HRQoL was associated with anogenital involvement.73 In 
contrast, in another study there was no difference in DLQI scores between men and women. 
Male patients had higher sexual dysfunction and reduced QoL when compared to a control 
group. There was no significant difference between female patients with HS and controls 
regarding sexual functioning. The presence or absence of genital lesions in both male and female 
HS patients did not correlate with changes in DLQI scores or any sexual function measures.74 
Validation of HS clinical severity and response instruments 
QoL instruments were used in several studies in the cross-validation of several novel HS clinical 
severity and response instruments: Hidradenitis Suppurativa Score (HSS),75 Hidradenitis 
Suppurativa Clinical Response (HiSCR),76 Acne Inversa Severity Index (AISI)77 and 
International Hidradenitis Suppurativa Severity Score System (IHS4).7 
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Validation of HS-specific QoL instruments 
The initial validation of two HS-specific HRQoL instruments was reported.78,79 These HS-
specific instruments are described in detail below. 
Other findings related to QoL assessment in HS patients 
There was no differences in quimp between HS patients with different body mass index and 
between smokers and non-smokers with HS.5 HS patients had low physical and social 
functioning scores when assessed with the generic SF-36 HRQoL questionnaire.80 A high Hurley 
stage and female gender were variables that significantly correlated with the total DLQI score in 
a Finnish study of HS patients.81 Women in that study had consistently higher scores than men 
for every item of the DLQI. There was no significant correlation between resilience and  HRQoL 
in HS patients from US and Denmark.82 Profound impact on the HRQoL of Irish HS patients was 
reported, including diminished work productivity and various psychological comorbidities.83  
The severity of odour in HS patients was associated with total Skindex-29 scores but not with 
DLQI scores.84  In an international study of the QoL impact of treatment (the last DLQI item), 
over half of HS patients reported problems.85 The relationship of serum zinc levels with QoL and 
disease severity in HS was studied: low zinc levels were associated with DLQI ≥ 9.86  Self-
reported depression, anxiety and impaired QoL were strongly associated in HS with illness 
perceptions.87  QoL impairment was considered to be a predictor of the self-evaluated health 
status of HS patients.88  
HRQoL instruments 
Generic, dermatology-specific and HS-specific HRQoL instruments have all been used in HS 
(Figure 4). The DLQI was the most frequently used, in 84% of included studies. The second 
most frequently used instrument was another dermatology-specific questionnaire, Skindex-29 
(9% of studies). The DLQI is the most widely used HRQoL instrument in dermatology.  It is a 
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simple 10-question questionnaire covering six domains: Symptoms and feelings, Daily activities, 
Leisure, Work and School, Personal relationships and Treatment.  Responses are on a 4-point 
Likert scale: the higher the score, the more QoL is impaired. Test-retest reliability, internal 
consistency, construct validity, responsiveness, score band descriptors and MCID have been 
described for the DLQI. For general inflammatory skin conditions a change in DLQI score of at 
least 4 points is considered clinically important.89,90  
Three HS-specific HRQoL instruments were identified.  One was used in the assessment of 
efficacy of infliximab treatment in two Danish patients with severe fistulizing HS.24 This un-
named measure was a non-validated 10-item questionnaire focused on perianal problems (6 of 10 
items) that was adopted from an instrument used for Crohn’s disease.  
Another HS-specific questionnaire was developed based on interviews with 21 patients and the 
opinions of three experts: it was modified after pilot testing in nine patients. Responses are on a 
5-point Likert scale and higher scores indicate a worse QoL.91 Based on results of preliminary 
validation in 55 HS patients the number of items of the HS-QoL was reduced from 53 to 44, 
resulting in a seven subscales: Physical consequences, HS symptoms, Sexual activity 
consequences, Emotional consequences, Social consequences, Work consequences and Social 
support. The HS-QoL has a 6-months recall period. Internal consistency and convergent validity 
of the HS-QoL questionnaire were checked.78  
The third HS-specific HRQoL instrument, the Hidradenitis Suppurativa Burden of Disease 
(HSBOD), was developed based on interviews with patients (number of patients not presented) 
and eight dermatologists.79 The HSBOD is a 19-item questionnaire with 5 domains: Symptoms 
and feelings, Daily activities, Leisure, Work/school and Personal relationships. Responses are on 
a 10-cm visual analog scale (VAS). It is divided into two parts with different recall periods: the 
last 4 weeks (14 items) and the entire time of having HS (5 items). The internal consistency and 
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convergent validity of the HSBOD questionnaire were checked in studies that included 29 HS 
patients. 
Discussion 
HS results in significant quimp that is higher than in most other chronic skin diseases. Pain and 
HS symptoms have the highest influence on HRQoL. The social and sexual life of patients may 
be severely affected. In some studies female HS patients and those with genital involvement 
experienced higher quimp.  
Several studies showed that, after initial improvement, the HRQoL of HS patients may worsen 
again.31,33 It seems that surgical treatment has the best effect on the HRQoL of HS patients over a 
long-term perspective. There is a lack of well-organized placebo controlled clinical trials with 
sufficient participant numbers that assess different treatment methods. 
Several reports have advocated the importance of HS-specific HRQoL instruments.11,15  Some 
HRQoL measures used in HS have been based on a mixture of clinician opinion, literature 
review and patient input. However, the question content of HRQoL measures should ideally be 
based solely on the actual experiences of patients, as is the case for the most widely used 
instruments in dermatology. This is perhaps why those instruments have been so widely accepted 
worldwide.92 In order for QoL measurement to be carried out routinely in a busy clinic, it is 
essential that the measure used be short, easy to understand, able to be completed unaided and 
have a simple method of scoring.92 In this context the HSBOD with 19 items could be potentially 
more practical than the HS-QoL with 44 items. However, the combination of two different recall 
periods in a single instrument, as in the case of the HSBOD, may complicate interpretation and 
especially responsiveness of the instrument’s scores. Only the first 14 items of the HSBOD may 
be used as an outcome measure to assess response to intervention, as the other five items record 
lifetime experience. The length of the six months recall period of the HS-QoL questionnaire, 
while gathering more information, may introduce response bias and precludes frequent use.93 
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Two of the HS-specific instruments use different scoring systems, the Likert scale and the visual 
analogue scale (VAS). Single VAS questions can, in some questionnaires of uniform construct, 
replace a single Likert item and also be comparable, but not interchangeable, with multi-item 
Likert indices.94 Children prefer the Likert scale over the VAS and find it easier to complete.95 
An acknowledged limitation of the HSBOD is that it requires abstract thinking, which may be 
difficult for some patients.79  
Recommendations for treatment strategy based on HS severity and HRQoL changes, as is now 
standard in psoriasis, may be beneficial. This approach was already taken concerning long-term 
adalimumab efficacy in HS patients.35  
The position statement of the EADV TFs is that “HRQoL assessment should be widely used in 
the management of HS patients.”   However there is a lack of high quality clinical trials in HS 
patients where HRQoL instruments have been used as outcome measures. Well-designed clinical 
studies in HS patients to compare different treatment methods, including surgical methods and 
assessing long-term effects are needed.  Because of lack of sufficient validation, the Task Forces 
are not at present able to recommend existing HS-specific HRQoL instruments for use in clinical 
studies.  The EADV TFs recommend the dermatology-specific DLQI questionnaire for use in HS 
patients. The DLQI’s MCID may be used as a marker of minimal treatment efficacy and the 
DLQI of 0-1, corresponding to “no effect on patient’s life” according to the DLQI banding 
descriptions, may be considered as a difficult to reach but important treatment goal. The EADV 
TFs encourage the further development, validation and use of other HS-specific, dermatology-
specific and generic instruments but such use should be based on the principles presented in the 
previous publications of the EADV TF on QoL and Patient Oriented Outcomes.96-100 
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